SEC Form 8-K Summary
Registrant: MedTech Acquisition Corporation (MTAC), which proposed to combine with TriSalus Life Sciences, Inc. The report was filed November 14, 2022, regarding events occurring primarily on November 11, 2022.
Business Context and Transaction
MTAC entered into a merger agreement with TriSalus and MTAC Merger Sub, Inc. Merger Sub is expected to merge with TriSalus, with TriSalus surviving as a wholly owned subsidiary of MTAC. Following closing, MTAC is expected to be renamed TriSalus Life Sciences, Inc.
The aggregate merger consideration is $220 million, payable solely in MTAC common stock valued at $10.00 per share. TriSalus preferred stock is expected to convert into common stock before closing. In-the-money TriSalus warrants are expected to be exercised or exchanged, while out-of-the-money warrants will be cancelled without consideration. TriSalus equity awards will be assumed and converted into MTAC options.
Financial Metrics, Liquidity and Capitalization
- The filing does not provide clear operating revenue, profit, cash flow, margin, or debt figures for TriSalus or MTAC.
- Closing requires MTAC to have at least $60 million of Available Closing Acquiror Cash, after redemptions and certain transaction expenses, including an expense cap of up to $6 million subject to potential increases.
- MTAC must have at least $5,000,001 of net tangible assets at closing.
- MTAC and TriSalus entered into a non-binding term sheet with Magnetar Capital for up to $50 million of 8.0% senior secured convertible notes at closing, with an option for additional notes that could result in total potential issuance of up to $100 million. The financing remains subject to due diligence, definitive documentation, and other conditions.
- Raymond James agreed to waive deferred underwriting fees and commissions that otherwise would have been payable if the business combination closes.
Material Changes and Transaction Terms
- MTAC’s sponsor agreed to vote its shares in favor of the transaction, assume transaction expenses above the applicable cap, forfeit 2,187,500 shares, and subject 3,125,000 shares to vesting restrictions. These forfeiture and vesting provisions become void if the support agreement or merger agreement is terminated.
- TriSalus-designated stockholders agreed to support and vote for the transaction, waive applicable dissenters’ or approval rights, and observe transfer restrictions.
- After closing, the parties intend to establish a nine-member classified board: seven directors designated by TriSalus and two designated by MTAC, with at least a majority of the TriSalus-designated directors expected to qualify as independent under Nasdaq rules.
- Certain TriSalus stockholders will be subject to lock-ups ending at the earliest of 365 days after closing, specified trading-price conditions involving a $12.00 share price, or certain change-of-control events.
- An amended registration rights agreement is expected to require a registration statement covering investor shares within 45 days after closing and to provide demand and piggyback registration rights.
Conditions, Outlook and Risks
- Closing requires approval by MTAC and TriSalus stockholders, Nasdaq approval for the shares to be issued, satisfaction of minimum cash and net tangible asset requirements, and other customary conditions.
- A key condition relates to reimbursement for TriSalus’s TriNav Infusion System for calendar year 2023. The required reimbursement pathway must be extended, made permanent, or provide adequate profitability through existing reimbursement codes.
- The agreement may be terminated if closing does not occur by December 22, 2022, subject to extensions of MTAC’s business-combination deadline up to June 22, 2023; if applicable approvals are not obtained; if material breaches are not cured; or under other specified circumstances.
- Either party may terminate if MTAC has not obtained commitments for at least $40 million of private financing by March 31, 2023.
- The filing identifies risks involving stockholder redemptions, insufficient financing, reimbursement and regulatory approvals, TriNav sales and commercialization, clinical and product-development outcomes, competition, Nasdaq listing, litigation, transaction costs, and failure to complete or realize the expected benefits of the business combination.
- The proposed Magnetar financing is non-binding apart from specified exclusivity, expense reimbursement, and indemnity provisions. It is also conditioned in part on TriSalus obtaining or securing specified reimbursement codes by January 31, 2023.
- TriSalus financial information included in the filing is described as preliminary, unaudited, and not compliant with Regulation S-X; actual results may differ materially.
Most Important Facts to Verify
- Whether MTAC and TriSalus stockholders approved the transaction and whether the merger ultimately closed.
- Available cash at closing after public-stockholder redemptions and transaction expenses.
- Whether the Magnetar convertible-note financing was finalized, including principal amount, conversion terms, security, and subsequent funding options.
- Whether TriNav reimbursement requirements were satisfied and whether reimbursement levels support adequate profitability.
- The final number of MTAC shares issued, post-closing ownership, sponsor forfeitures and vesting outcomes, and dilution from assumed options, warrants, and convertible notes.
- The effectiveness of the Form S-4 registration statement and the final audited financial statements and pro forma information.